Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07286266 | A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) | PHASE3 | NOT YET_RECRUITING | 450 | — | — | Jun 24, 2026 | Aug 21, 2030 | May 27, 2026 | - | — |
PFS is defined as the time from the date of randomization to the date of first documented Progressive Disease (PD) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) by Blinded independent central review (BICR) assessment or death from any cause, whichever occurs first.
OS is defined as the time from the date of randomization to the date of death due to any cause
| Arm | Type | Description |
|---|---|---|
| Mocertatug rezetecan | EXPERIMENTAL | Participants will receive Mocertatug rezetecan |
| Standard of care | ACTIVE_COMPARATOR | Participants will receive standard of care chemotherapy (Paclitaxel or Pembrolizumab + paclitaxel ± bevacizumab or PLD or Topotecan or Gemcitabine) as per investigator's choice |
| Name | Type | Description |
|---|---|---|
| Mocertatug rezetecan | DRUG | Mocertatug rezetecan will be administered |
| Paclitaxel | DRUG | Paclitaxel will be administered |
| Pegylated liposomal doxorubicin (PLD) | DRUG | PLD will be administered |
| Topotecan | DRUG | Topotecan will be administered |
| Gemcitabine | DRUG | Gemcitabine will be administered |
| Pembrolizumab | DRUG | Pembrolizumab will be administered |
| Bevacizumab | DRUG | Bevacizumab will be administered |
Inclusion Criteria: * Is at least 18 years of age and the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed Consent Form (ICF). * Has epithelial ovarian cancer, inclusive of primary peritoneal or fallopian-tube cancer with a histological...